OverviewSuggest Edit
Abcam is a producer and distributor of research-grade antibodies and associated products. The Company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders.
| Type | Public | |
| Founded | 1998 | |
| HQ | Cambridge, GB | Map |
| Website | abcam.com | |
| Employee Ratings | More |
Recent NewsAll News
- Cancer Research UK and Abcam Launch Custom Partnership to Accelerate Cancer Research
- Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell's Gene Editing Platform and Oncology Product Portfolio
- Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability
- Abcam and BrickBio announce a partnership to incorporate conjugation-ready sites into recombinant antibodies across Abcam's portfolio
Key People/Management at Abcam
Alan Hirzel
CEO
Abcam Office Locations
Abcam has offices in Cambridge, Branford, Burlingame, Eugene and in 5 other locations
Cambridge, GB (HQ)
Discovery Drive Cambridge Biomedical Campus, Trumpington
Shanghai, CN
Galileo Rd. Pudong
Tokyo, JP
2-2-1 Nihonbashi Horidome-cho
Branford, US
Branford, CT, USA
Burlingame, US
Burlingame, CA, USA
Cambridge, US
1 Kendall Sq B2304
Abcam Financials and Metrics
Abcam Revenue
Abcam's revenue was reported to be £259.90 m in FY, 2019
| GBP | |
|---|---|
Revenue (FY, 2019) | 259.9m |
Gross profit (FY, 2019) | 183.2m |
Gross profit margin (FY, 2019), % | 70.5% |
Net income (FY, 2019) | 45.0m |
EBIT (FY, 2019) | 56.1m |
Market capitalization (15-Sept-2020) | 2.7b |
Closing stock price (15-Sept-2020) | 12.5 |
Cash (30-Jun-2019) | 87.1m |
EV | 2.6b |
Abcam's current market capitalization is £2.7 b.
| GBP | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 248.4k | 719.6k | 1.8m | 3.5m | 6.7m | 12.1m | 19.4m | 24.5m | 36.7m | 56.8m | 71.1m | 83.3m | 97.8m | 122.2m | 128.0m | 144.0m | 171.7m | 217.1m | 233.2m | 259.9m |
Revenue growth, % | 13% | 19% | ||||||||||||||||||
Cost of goods sold | 160.4k | 416.1k | 820.6k | 1.4m | 2.5m | 4.7m | 7.5m | 10.0m | 14.4m | 19.4m | 23.7m | 27.2m | 30.3m | 35.5m | 37.6m | 42.5m | 51.1m | 65.0m | 70.2m | 76.7m |
Gross profit | 88.0k | 303.5k | 983.7k | 2.1m | 4.2m | 7.5m | 11.9m | 14.5m | 22.3m | 37.4m | 47.4m | 56.0m | 67.6m | 86.7m | 90.4m | 101.5m | 120.5m | 152.1m | 163.0m | 183.2m |
| GBP | FY, 1999 | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 9.6k | 269.1k | 87.3k | 59.1k | 66.1k | 274.3k | 510.0k | 884.0k | 2.2m | 13.5m | 25.5m | 40.2m | 55.6m | 14.0m | 37.3m | 55.3m | 57.1m | 68.9m | 84.8m | 90.2m | 87.1m |
Accounts Receivable | 55.1k | 158.6k | 261.0k | 424.8k | 926.8k | 1.7m | 2.4m | 3.3m | 3.7m | 5.4m | 6.8m | 7.9m | 11.5m | 12.1m | 13.2m | 19.6m | 22.0m | 24.9m | 29.3m | ||
Inventories | 3.2k | 4.0k | 18.1k | 69.4k | 185.9k | 557.8k | 1.2m | 2.4m | 3.1m | 4.5m | 6.8m | 9.1m | 10.7m | 15.4m | 15.3m | 14.8m | 19.8m | 19.7m | 21.8m | 29.6m | 36.0m |
Current Assets | 33.6k | 362.3k | 320.8k | 696.5k | 864.3k | 2.7m | 4.6m | 17.0m | 18.1m | 23.9m | 40.1m | 58.5m | 76.4m | 48.7m | 71.3m | 90.9m | 100.5m | 119.7m | 143.5m | 159.9m | 171.8m |
| GBP | FY, 2000 | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (190.1k) | (471.9k) | (328.2k) | 517.2k | 1.0m | 2.3m | 3.7m | 4.1m | 5.9m | 12.3m | 19.2m | 23.8m | 25.4m | 32.7m | 34.0m | 37.4m | 37.4m | 42.4m | 62.2m |
Cash From Operating Activities | 2.6m | 3.5m | 4.9m | 7.1m | 14.8m | 19.7m | 25.5m | 24.5m | 39.4m | 41.3m | 40.2m | 47.3m | 66.4m | 63.3m | |||||
Dividends Paid | 300.0k | 1.3m | 1.2m | 968.0k | 2.6m | 5.3m | 7.9m | 10.1m | 12.5m | 11.3m | 15.9m | 16.7m | 19.1m | 22.1m | |||||
Cash From Financing Activities | 570.0k | 9.3m | 47.0k | (2.2m) | (1.2m) | (27.4m) | (7.6m) | 10.7m | (11.8m) | (13.8m) | (14.1m) | (15.4m) | (17.8m) | (20.6m) |
| GBP | FY, 1999 |
|---|---|
Financial Leverage | -0.6 x |
Abcam Cybersecurity Score
Abcam Online and Social Media Presence
6.61k Twitter followers
Abcam has 6.61k Twitter Followers. The number of followers has increased 0.7% month over month and increased 3% quarter over quarter
Abcam's Trends
Twitter Engagement Stats for @abcam
6.3k
Tweets
967
Following
6.6k
Followers
40
Tweets last 30 days
2.9
Avg. likes per Tweet
97.5%
Tweets with engagement
Abcam News and Updates
July 07, 2020
Cancer Research UK and Abcam Launch Custom Partnership to Accelerate Cancer Research
LONDON and CAMBRIDGE, England, July 7, 2020 /PRNewswire/ -- Today, Cancer Research UK, the world's largest independent funder of cancer research and Abcam plc, a global innovator in life science reagents and tools, are pleased to announce a new partnership for the development and...
January 30, 2020
Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell's Gene Editing Platform and Oncology Product Portfolio
CAMBRIDGE, England and MILPITAS, California, Jan. 30, 2020 /PRNewswire/ -- Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life...
January 06, 2020
Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability
CAMBRIDGE, England, Jan. 6, 2020 /PRNewswire/ -- Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences, as of 1st...
November 08, 2019
Abcam and BrickBio announce a partnership to incorporate conjugation-ready sites into recombinant antibodies across Abcam's portfolio
CAMBRIDGE, England and BOSTON, Nov. 8, 2019 /PRNewswire/ -- Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce a strategic partnership with BrickBio, experts in site-specific protein modification and a Tiger Gene portfolio company, covering the...
October 29, 2019
Epigenetics Market Overview & Potential Growth Opportunities Report To 2025 | Key Players: Illumina, Abcam, Novartis, Merck & Oncolys Biopharma | Million Insights
FELTON, California, Oct. 29, 2019 /PRNewswire/ -- The global Epigenetics Market is expected to value at USD 22.05 billion in 2025, exhibiting a CAGR of 19.7% during the forecast period of 2018 to 2025. Rapid surge in the product demand is credited to the ever-growing geriatric population...
January 15, 2019
Detailed Examination of the Global Life Science Reagent Market Forecast to 2025: High Throughput Genomics Inc., Illumina Inc., Abbott Laboratories, Abcam
Life Science Reagents are the substances or compounds used to detect or synthesize another substance in order to provide a test reading. These reagents are used in the field of research, diagnosis, bioscience, and education. Posted via Industry Today. Follow us on Twitter @IndustryToday
Abcam Blogs
April 23, 2020
Adapt to Working from Home: our Tipbox tips
Many people rarely work from home. Therefore, it can be quite a change to be suddenly told to leave the comforts of the bench or office to work in our own accommodation. Consequently, this poses the challenge of setting up an effective workspace and adapting to working from home, rapidly. Several st…
April 20, 2020
Seven inspiring women in science you may never have heard of
As March is Women’s History Month, we would like to celebrate it by sharing seven stories of incredible female scientists. We all know about such giants of science as Marie Curie, Rosalind Franklin and Ada Lovelace. However, today we want to recognize the scientific contributions of less-known women…
March 09, 2020
Spring Photography Competition
Calling all budding photographers! Spring is just around the corner: the days are getting longer, the temperatures are getting warmer, and we are becoming tempted by all the Easter eggs lining the shelves. As a scientist, it is the perfect time to stretch your legs on the way into the lab and use th…
February 24, 2020
How to write your PhD thesis and keep calm
Many factors may complicate how you feel as you approach the end-phase of your PhD. You may be stressed about applying for jobs. You may still be finishing some experiments for a publication (or for the final chapter of your thesis!). You may just be one of the many scientists who don’t enjoy writin…
October 31, 2019
Master your science communication: an interview with Dr. Adam Rutherford
Science communication is something we take seriously at Tipbox. We’ve run a panel discussion on the topic, heard our readers sci-comm tales, and now we’ve got the low down from one of science communication’s biggest believers, Dr. Adam Rutherford. You may be familiar with Adam’s work on BBC Radio 4 …
October 15, 2019
Medicine and Genomics: a tale of two subjects
Getting into a medical career can be a long and difficult pursuit. Many students fresh out of their studies will dream of getting a place on a medical degree course but the reality is that for many of these students this dream just doesn’t quite become a reality. We caught up with brand new medical …
Abcam Frequently Asked Questions
When was Abcam founded?
Abcam was founded in 1998.
Who are Abcam key executives?
Abcam's key executives are Alan Hirzel.
How many employees does Abcam have?
Abcam has 948 employees.
What is Abcam revenue?
Latest Abcam annual revenue is £259.9 m.
What is Abcam revenue per employee?
Latest Abcam revenue per employee is £274.2 k.
Who are Abcam competitors?
Competitors of Abcam include Humanigen, Avadim Health and Optibiotix Health.
Where is Abcam headquarters?
Abcam headquarters is located at Discovery Drive Cambridge Biomedical Campus, Trumpington, Cambridge.
Where are Abcam offices?
Abcam has offices in Cambridge, Branford, Burlingame, Eugene and in 5 other locations.
How many offices does Abcam have?
Abcam has 10 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies